ACP-044

Acadia's prized pain drug from $52M buyout flops its first test
Endpoints
Tue, 04/19/22 - 10:57 am
Acadia Pharmaceuticals
CerSci Therapeutics
M&A
ACP-044
non-opioid pain treatments